With regard to other antineoplastic agents, IA arthritis has been more frequently observed as a side effect of anti-PD-1 ICI agents,[15,19] and it may also develop after the administration of anti-CTLA-4 antibodies. The gene discussed is CTLA4; the disease is arthritic joint disease.